

General information about company

Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2020
Date of end of financial year	31-03-2021
Date of board meeting when results were approved	21-08-2020
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	14-08-2020
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs
Start date and time of board meeting	21-08-2020 12:30
End date and time of board meeting	21-08-2020 17:00
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020	01-04-2020
B	Date of end of reporting period	30-06-2020	30-06-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	5474.9	5474.9
	Other income	30.29	30.29
	Total income	5505.19	5505.19
2	Expenses		
(a)	Cost of materials consumed	2459.73	2459.73
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	619.43	619.43
(d)	Employee benefit expense	606.26	606.26
(e)	Finance costs	118.7	118.7
(f)	Depreciation, depletion and amortisation expense	194.76	194.76
(f)	Other Expenses		
1	Manufacturing Expenses	807.32	807.32
2	Other Expenses	342.62	342.62
10			
	Total other expenses	1149.94	1149.94
	Total expenses	5148.82	5148.82

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020	01-04-2020
B	Date of end of reporting period	30-06-2020	30-06-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	356.37	356.37
4	Exceptional items	0	0
5	Total profit before tax	356.37	356.37
7	Tax expense		
8	Current tax	101	101
9	Deferred tax	7.11	7.11
10	Total tax expenses	108.11	108.11
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	248.26	248.26
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	248.26	248.26

Financial Results – Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020	01-04-2020
B	Date of end of reporting period	30-06-2020	30-06-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	6.44	6.44
3 Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	-1.88	-1.88
5	Total Other comprehensive income	-4.56	-4.56

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020	01-04-2020
B	Date of end of reporting period	30-06-2020	30-06-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	243.7	243.7
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	8.21	8.21
	Diluted earnings (loss) per share from continuing operations	8.21	8.21
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	8.21	8.21
	Diluted earnings (loss) per share from continuing and discontinued operations	8.21	8.21
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)

1. The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 21st August, 2020 and have been approved by the Board of Directors at its meeting held on 21st August, 2020.
2. Results for the quarter ended 30th June, 2020 were subjected to 'Limited Review' by the Auditors and their report contains no qualifications.
3. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The figures for the quarter ended 31st March, 2020 are the balancing figures between audited figures in respect of full financial year upto 31st March, 2020 and the unaudited published year to date figures upto 31st December, 2019 being the date of the end of the third quarter of the financial year which were subjected to limited review.
5. Sales for the quarter ended June 30th, 2020 has increased by 20% as compared to previous quarter ended March 31st, 2020 whereas revenue has decreased by 40% compared to the corresponding quarter ended June 30th, 2019 due to NOMA issue in Ranitidine HCl. The company is also focusing to manufacture and sell other new molecules developed by its own R&D along with few contract manufacturing co-partners resulting in increasing the revenues as well as margins. In addition to this the Company is evaluating import substitution products and opportunities arising out of COVID-19.
6. The Consolidated un audited financial results include the un audited financial results of Mahi Drugs Private Limited a wholly owned subsidiary
7. The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
8. The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
9. Figures of previous period have been regrouped & rearranged wherever necessary to confirm to the current period's classification.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2020	01-04-2020
Date of end of reporting period	30-06-2020	30-06-2020
Whether accounts are audited or unaudited		
Nature of report standalone or consolidated	Consolidated	Consolidated
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		